Verve Pipeline Progress and Reports First Quarter 2025 Financial Results

Verve Therapeutics (VERV) reported promising Q1 2025 results and significant progress in its cardiovascular disease pipeline. The company's lead candidate VERVE-102 showed positive initial data from the Heart-2 Phase 1b trial, achieving a mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg dose cohort. The drug demonstrated a favorable safety profile with no serious adverse events. VERVE-102 received FDA Fast Track designation for hyperlipidemia treatment. The company's second candidate, VERVE-201 targeting ANGPTL3, continues progression in the Pulse-1 Phase 1b trial. Financially, Verve maintains a strong position with $497.1 million in cash and equivalents, providing runway into mid-2027. Q1 2025 saw collaboration revenue of $33.0 million and a net loss of $31.0 million ($0.35 per share).

https://www.stocktitan.net/news/VERV/verve-therapeutics-announces-pipeline-progress-and-reports-first-o0eap36wg7oj.html